Shortening the infusion time of anticancer drugs: Who will benefit?

Journal of Clinical Oncology

Volumn 25, Issue 19, 2007, Pages 2642-2643

  Margolin, Kim ^a   Gordon, Michael ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b Premiere Oncology of Arizona   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CREMOPHOR; DEXAMETHASONE; FLUOROURACIL; FOLINIC ACID; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; RITUXIMAB;

CANCER PAIN; CLINICAL TRIAL; COLORECTAL CANCER; COST BENEFIT ANALYSIS; DOSE TIME EFFECT RELATION; DRUG APPROVAL; DRUG COST; DRUG HYPERSENSITIVITY; DRUG SAFETY; EDITORIAL; FLUSHING; HUMAN; HYPERTENSION; HYPOTENSION; HYPOXIA; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHODGKIN LYMPHOMA; PATIENT IDENTIFICATION; PRIORITY JOURNAL; QUALITY OF LIFE; RIGOR; SIDE EFFECT; SOLID TUMOR; URTICARIA; VOMITING; ECONOMICS; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; NEOPLASM; NOTE; ONCOLOGY; PROSPECTIVE STUDY; TIME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; MEDICAL ONCOLOGY; NEOPLASMS; PROSPECTIVE STUDIES; QUALITY OF LIFE; TIME FACTORS;

EID: 34447570856     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.10.7334     Document Type: Editorial

References (11)

1. Reidy DL, Chung KY, Timoney JP, et al: Bevacizumab 5 mg/kg can be infused safely over 10 minutes. J Clin Oncol 25:2691-2695, 2007
2. Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927-1932, 1998
3. Cobleigh MA, Langmuir VK, Sledge GW, et al: A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30:117-124, 2003 (suppl 16)
4. Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003
5. Hurwitz H, Fehrenbacher L, Hainsworth J, et al: Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23:3502-3508, 2005
6. Miller KD, Wang M, Gralow J, et al: E2100: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13-17, 2005.
7. Cole BF, Gelber RD, Gelber S, et al: A quality-adjusted survival (Q-TWiST) model for evaluating treatments for advanced stage cancer. J Biopharm Stat 14:111-124, 2004
8. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
9. Sandler A, Gray R, Perry M, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2549, 2006
10. Berenson A: A cancer drug shows promise, at a price that many can't pay. New York Times, Feb 15, 2006
11. Jain R, Duda D, Clark J, et al: Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3:24-40, 2006